US Pharma MarketingNovartis sinks after second disastrous trial failure, this time of Avidity-acquired drug
Novartis Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
In the wake of its high-profile setback in heart disease late last week, Novartis really needed a win.
It didn’t get one.
The Swiss pharma said Tuesday that in a late-stage ...
Source: Endpoints News